MetaCap

DBV Technologies S.A. (DBVT) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iambic Therapeutics is the larger company by market cap ($621.4 million vs $566.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DBVT-0.99%IAM-30.67%
+34%-8%-50%
Oct 15, 20261 yearNov 20, 2026
DBVT-0.33%IAM-44.94%
+26%-18%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DBVT versus IAM key metrics
MetricDBVTIAM
Share price$9.02$13.11
Market cap$566.82M$621.42M
1-day change-4.25%-8.06%
YTD return-52.95%—
1-year return-34.40%—
5-year return+50.33%—
EPS (TTM)$-3.00$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.64M—
Revenue growth (YoY)+35.77%—
Net income (latest FY)$-146.95M—
Operating margin-2609.23%—
Net margin-2607.29%—
52-week high$26.19$25.00
52-week low$8.63$9.60
Distance from 52-week high-65.55%-47.56%
Analyst consensusbuystrong_buy
Avg. price target upside+305.10%+107.86%
Average volume352.88K714.92K
Shares outstanding62.84M47.40M
Employees179171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About DBV Technologies S.A.

DBVT stock →

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

DBVT vs IAM FAQ

Which is bigger, DBV Technologies S.A. or Iambic Therapeutics?

Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $566.82M for DBV Technologies S.A. (DBVT).

Are DBV Technologies S.A. and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons